SQ109 to be evaluated for efficacy on multi-drug resistant patients

Maxwell Biotech Venture Fund’s portfolio company, Infectex, receives Russian regulator’s approval to conduct pivotal clinical trial for Sequella’s antibiotic, SQ109, for tuberculosis.